Targeting glycolysis: exploring a new frontier in glioblastoma therapy
Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherap...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522392/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540110649131008 |
|---|---|
| author | Lu Yang Sijia Li Lei Yu Jiao Leng Na Li |
| author_facet | Lu Yang Sijia Li Lei Yu Jiao Leng Na Li |
| author_sort | Lu Yang |
| collection | DOAJ |
| description | Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, have limited efficacy.In recent years, the role of glycolytic metabolic reprogramming in GBM has garnered increasing attention. This review delves into the pivotal role of glycolytic metabolic reprogramming in GBM, with a particular focus on the multifaceted roles of lactate, a key metabolic product, within the tumor microenvironment (TME). Lactate has been implicated in promoting tumor cell proliferation, invasion, and immune evasion. Additionally, this review systematically analyzes potential therapeutic strategies targeting key molecules within the glycolytic pathway, such as Glucose Transporters (GLUTs), Monocarboxylate Transporters(MCTs), Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate Kinase Isozyme Type M2 (PKM2), and the Lactate Dehydrogenase A (LDHA). These studies provide a novel perspective for GBM treatment. Despite progress made in existing research, challenges remain, including drug penetration across the blood-brain barrier, side effects, and resistance. Future research will aim to address these challenges by improving drug delivery, minimizing side effects, and exploring combination therapies with radiotherapy, chemotherapy, and immunotherapy to develop more precise and effective personalized treatment strategies for GBM. |
| format | Article |
| id | doaj-art-549bed11433f4a838445eff7f06f76a2 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-549bed11433f4a838445eff7f06f76a22025-01-14T06:10:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15223921522392Targeting glycolysis: exploring a new frontier in glioblastoma therapyLu YangSijia LiLei YuJiao LengNa LiGlioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, have limited efficacy.In recent years, the role of glycolytic metabolic reprogramming in GBM has garnered increasing attention. This review delves into the pivotal role of glycolytic metabolic reprogramming in GBM, with a particular focus on the multifaceted roles of lactate, a key metabolic product, within the tumor microenvironment (TME). Lactate has been implicated in promoting tumor cell proliferation, invasion, and immune evasion. Additionally, this review systematically analyzes potential therapeutic strategies targeting key molecules within the glycolytic pathway, such as Glucose Transporters (GLUTs), Monocarboxylate Transporters(MCTs), Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate Kinase Isozyme Type M2 (PKM2), and the Lactate Dehydrogenase A (LDHA). These studies provide a novel perspective for GBM treatment. Despite progress made in existing research, challenges remain, including drug penetration across the blood-brain barrier, side effects, and resistance. Future research will aim to address these challenges by improving drug delivery, minimizing side effects, and exploring combination therapies with radiotherapy, chemotherapy, and immunotherapy to develop more precise and effective personalized treatment strategies for GBM.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522392/fullglioblastomaglycolytic metabolic reprogramminglactatetumor microenvironmenttargeted therapy |
| spellingShingle | Lu Yang Sijia Li Lei Yu Jiao Leng Na Li Targeting glycolysis: exploring a new frontier in glioblastoma therapy Frontiers in Immunology glioblastoma glycolytic metabolic reprogramming lactate tumor microenvironment targeted therapy |
| title | Targeting glycolysis: exploring a new frontier in glioblastoma therapy |
| title_full | Targeting glycolysis: exploring a new frontier in glioblastoma therapy |
| title_fullStr | Targeting glycolysis: exploring a new frontier in glioblastoma therapy |
| title_full_unstemmed | Targeting glycolysis: exploring a new frontier in glioblastoma therapy |
| title_short | Targeting glycolysis: exploring a new frontier in glioblastoma therapy |
| title_sort | targeting glycolysis exploring a new frontier in glioblastoma therapy |
| topic | glioblastoma glycolytic metabolic reprogramming lactate tumor microenvironment targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522392/full |
| work_keys_str_mv | AT luyang targetingglycolysisexploringanewfrontieringlioblastomatherapy AT sijiali targetingglycolysisexploringanewfrontieringlioblastomatherapy AT leiyu targetingglycolysisexploringanewfrontieringlioblastomatherapy AT jiaoleng targetingglycolysisexploringanewfrontieringlioblastomatherapy AT nali targetingglycolysisexploringanewfrontieringlioblastomatherapy |